Session Information

Register For TLM 2022

Pan-society Presentation of NAFLD Nomenclature Consensus Process

Date: Sunday, November 6th
Time: 4:00 - 6:00 PM EST
Room: Ballroom ABC

About the Session

In early 2021, a global effort was established to explore the appropriateness and ramifications of a potential re-naming of Nonalcoholic Fatty Liver Disease (NAFLD). In addition to evaluating the current name, if the process determined that a change was appropriate, a key additional goal is to consider which replacement term would best reflect our evolving understanding of the pathophysiology of NAFLD while allowing for the incorporation of future knowledge. In considering the nomenclature, the consensus process sought to better understand the impact of stigma and awareness on patients and caregivers globally.

Over the last two years, a group of 264 global experts from 56 countries have participated in multiple survey rounds utilizing the delphi process. Additionally, a group of 122 participants (54% of survey respondents) from 32 countries participated in an interactive Nomenclature Summit in Chicago, USA in July 2022 to discuss and evaluate the results of the first two delphi rounds. This project has been supported by more than a dozen professional societies and patient groups around the world.

The purpose of this session is to update attendees on the process and key findings of this Delphi process and to engage in discussion with the global community.

Learning Objectives

  • Provide an update on the NAFLD Nomenclature Consensus Process
  • Present key findings and proposals developed via the process
  • Propose next steps to complete the process


Dr. Fasiha Kanwal, MD, MSHS, AGAF, FAASLD, Baylor College of Medicine Prof. Philip N Newsome, MD, PhD, University Hospitals Birmingham NHS Foundation Trust Dr. Arun J Sanyal, MD, FAASLD, Virginia Commonwealth University, Division of Gastroenterology, Hepatology and Nutrition Dr. Mary E Rinella, MD, FAASLD, University of Chicago Medicine, Transplant Hepatology Dr. Laurie D DeLeve, MD, PhD, FAASLD, Keck Medicine of USC, USC Division of Gastrointestinal and Liver Disease and the USC Research Center for Liver Disease Mrs. Donna Cryer, JD, Global Liver Institute Prof. Shiv Kumar Sarin, MD, FAASLD, Institute of Liver and Biliary Sciences Dr. Vincent Wong, MD, The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Medical Data Analytics Centre (MDAC), Institute of Digestive Disease Dr. Silvia C. Sookoian, MD, PhD, FAASLD, Institute of Medical Research (IDIM), School of Medicine, University of Buenos Aires and National Scientific and Technical Research Council (CONICET), Clinical and Molecular Hepatology Prof. Quentin M. Anstee, MBBS, PhD, FRCP, Newcastle Nihr Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust Dr. Marco Arrese, MD, FAASLD, Department of Gastroenterology, Escuela De Medicina, Pontificia Universidad Católica De Chile, Santiago, Chile Prof. Sven M. Francque, MD, PhD, Antwerp University Hospital Dr. Graciela Castro Narro, Centro Médica Sur, México Prof. Jeffrey V. Lazarus, Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona Prof. Thomas Berg, MD, Universitätsklinikum Leipzig Robert Mitchell-Thain, Global Liver Institute Prof. Vlad Ratziu, MD, Hôpital La Pitié Salpêtrière, AP-HP, Paris, France, Hepato-Gastroenterology Prof. Shivaram Prasad Singh, DM, FACG, AGAF, FRCP [Edin]. , Kalinga Gastroenterology Foundation Dr. Manal F Abdelmalek, MD, MPH, FAASLD, Mayo Clinic, Medicine, Gastroenterology